Research analysts covering NEXIEN BIOPHARMA.
Recent press releases and 8-K filings for NXEN.
Nxera Pharma Receives Approval for Second QUVIVIQ® Manufacturing Site in Asia
NXEN
New Projects/Investments
Guidance Update
Product Launch
- Nxera Pharma Japan has received approval to establish a second API manufacturing facility in Asia for its insomnia treatment, QUVIVIQ® (daridorexant) 25 and 50 mg, in addition to its primary European site.
- This expansion aims to address expected demand growth for QUVIVIQ® in Japan and the broader Asia-Pacific region, where the product was launched in Japan in December 2024.
- The new facility is projected to reduce manufacturing costs and enhance profitability, with cost reduction benefits expected to begin in 2027 and contribute to the company's 2030 Vision of sales exceeding JPY 50 billion and a profit margin over 30%.
- Nxera's full-year sales forecast for QUVIVIQ® for the fiscal year ending December 2025 is JPY 4.0 to JPY 5.0 billion.
Oct 31, 2025, 6:37 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more